Back to search results

Observational Study of LibAirty Airway Clearance System for Bronchiectasis

This study is looking at how well the LibAirty™ Airway Clearance System works in adults with bronchiectasis (a lung condition where airways are damaged and widened). It's an observational study, meaning you would already be using the LibAirty™ system as prescribed by your doctor, and the study would simply observe your health outcomes. The main goal is to see how often people experience pulmonary exacerbations (flare-ups of their lung condition) over 12 months while using the device at home. You can join if you are 21 or older, have a diagnosis of bronchiectasis, and either have a daily cough or have had two or more lung flare-ups in the past year requiring antibiotics.

Study design
This is an observational study with 200 participants, meaning it will track people already using the LibAirty™ system as part of their regular care. It is an open-label study, so both you and your doctors will know you are using the device.
What's involved
You will use the LibAirty™ system at home as prescribed by your doctor for 12 months. During this time, information will be collected from your medical records and you will complete questionnaires during your regular clinic visits.
Compensation
Not stated in the trial record.
Follow-up
Your health will be observed for 12 months while you are using the LibAirty™ system.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07135284

Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)

Recruiting
Not specifiedAges 21+Observational
Synchrony-Medical, Ltd
~200 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Airway clearance system

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary endpoint for this study is the rate of pulmonary exacerbations (PE).
Measured over 12 months

Conditions

Bronchiectasis Adult

Explore related trials

Bronchiectasis

Where it's being run

3 sites across 3 states
Alabama1
Georgia1
South Carolina1

Who to contact

Clinical Research Cordinator
[email protected]
205.638.5134
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Daily productive cough (as determined by a treating physician)
OR Available documentation from the last 12 months of 2 or more pulmonary exacerbations requiring antibiotic therapy 3. Be at age ≥ 21 years 4. Prescribed and receives the LibAirty system for home use 5. Be on a standard of care treatment plan that includes at least one physician encounter every 6 months 6. No change in treatment for Bronchiectasis in the 2-month period prior to enrollment 7. Signed informed consent

What this trial measures

  • The primary endpoint for this study is the rate of pulmonary exacerbations (PE).12 months